Research Progress on Temozolomide Resistance Mechanisms and Strategies to Overcome Resistance
Journal of Chemical, Biological and physical sciences · 28.02.2026 · 16 (1)
DOI: 10.24214/jcbps.a.16.1.09816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical, Biological and physical sciences, online erschienen am 28.02.2026.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is a highly aggressive and low-survival grade IV malignant glioma.Currently, the main treatment for GBM involves surgical resection followed by adjuvant radiotherapy and chemotherapy.Temozolomide (TMZ) is a first-line drug for the clinical treatment of malignant gliomas.It is a prodrug of an alkylating agent that primarily targets tumor cell DNA, transferring methyl groups to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine), causing DNA alkylation damage and subsequently DNA cross-linking, leading to tumor cell death (Figure 1).TMZ resistance in GBM is a major cause of chemotherapy failure.The main resistance mechanisms include DNA damage repair mechanisms, non-coding RNAs, tumor microenvironment, abnormal signaling pathways, glioma stem cell theory, and tumor cell autophagy.This article reviews the resistance mechanisms of TMZ treatment for GBM in recent years and discusses the main strategies to overcome GBM resistance to TMZ.
Zitieren
APA
(2026). Research Progress on Temozolomide Resistance Mechanisms and Strategies to Overcome Resistance. Journal of Chemical, Biological and physical sciences, 16(1). https://doi.org/10.24214/jcbps.a.16.1.09816
Vancouver
Research Progress on Temozolomide Resistance Mechanisms and Strategies to Overcome Resistance. Journal of Chemical, Biological and physical sciences. 2026;16(1). doi:10.24214/jcbps.a.16.1.09816
BibTeX
@article{euvimed2026,
title = {Research Progress on Temozolomide Resistance Mechanisms and Strategies to Overcome Resistance},
journal = {Journal of Chemical, Biological and physical sciences},
year = {2026},
volume = {16},
number = {1},
doi = {10.24214/jcbps.a.16.1.09816}
}
EUVIMED